Does NATALIZUMAB Cause Bladder transitional cell carcinoma? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Bladder transitional cell carcinoma have been filed in association with NATALIZUMAB (TYRUKO). This represents 0.0% of all adverse event reports for NATALIZUMAB.
5
Reports of Bladder transitional cell carcinoma with NATALIZUMAB
0.0%
of all NATALIZUMAB reports
0
Deaths
3
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From NATALIZUMAB?
Of the 5 reports, 3 (60.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NATALIZUMAB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does NATALIZUMAB Cause?
Multiple sclerosis relapse (6,478)
Fatigue (4,456)
Multiple sclerosis (4,078)
Memory impairment (3,024)
Malaise (2,523)
Fall (2,481)
Headache (2,476)
Gait disturbance (2,427)
Prescribed underdose (2,162)
Maternal exposure during pregnancy (1,948)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which NATALIZUMAB Alternatives Have Lower Bladder transitional cell carcinoma Risk?
NATALIZUMAB vs NATALIZUMAB-SZTN
NATALIZUMAB vs NATAMYCIN
NATALIZUMAB vs NATEGLINIDE
NATALIZUMAB vs NAVITOCLAX
NATALIZUMAB vs NAXITAMAB-GQGK